The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | The European ...

The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis ...

To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.

Diversify Advisory Services LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free ...

The Israel-based company said it was 'deeply disappointed' by the EU's fine The EU said Teva had abused its dominant position in the medicine for multiple sclerosis in Belgium, the Czech Republic ...